These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 24823644)

  • 21. Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration.
    Guo J; Zeng H; Chen Y
    Mol Pharm; 2020 Apr; 17(4):1028-1048. PubMed ID: 32150417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design considerations for nanotherapeutics in oncology.
    Stylianopoulos T; Jain RK
    Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site.
    Gouarderes S; Mingotaud AF; Vicendo P; Gibot L
    Expert Opin Drug Deliv; 2020 Dec; 17(12):1703-1726. PubMed ID: 32838565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment.
    Mikhaylov G; Mikac U; Magaeva AA; Itin VI; Naiden EP; Psakhye I; Babes L; Reinheckel T; Peters C; Zeiser R; Bogyo M; Turk V; Psakhye SG; Turk B; Vasiljeva O
    Nat Nanotechnol; 2011 Aug; 6(9):594-602. PubMed ID: 21822252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
    Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
    Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel progress of drug delivery system for organelle targeting in tumour cells.
    He Z; Zhang Y; Khan AR; Ji J; Yu A; Zhai G
    J Drug Target; 2021 Jan; 29(1):12-28. PubMed ID: 32698651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor.
    Yunna C; Mengru H; Fengling W; Lei W; Weidong C
    Eur J Pharm Biopharm; 2021 Aug; 165():75-83. PubMed ID: 33991610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer drug delivery with nanoparticles.
    Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
    In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
    Muntimadugu E; Kommineni N; Khan W
    Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nano-immunotherapy: Overcoming tumour immune evasion.
    Guevara ML; Persano F; Persano S
    Semin Cancer Biol; 2021 Feb; 69():238-248. PubMed ID: 31883449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.
    de Maar JS; Sofias AM; Porta Siegel T; Vreeken RJ; Moonen C; Bos C; Deckers R
    Theranostics; 2020; 10(4):1884-1909. PubMed ID: 32042343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicine and drug delivery.
    Wei C; Wei W; Morris M; Kondo E; Gorbounov M; Tomalia DA
    Med Clin North Am; 2007 Sep; 91(5):863-70. PubMed ID: 17826106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.
    Dai Y; Xu C; Sun X; Chen X
    Chem Soc Rev; 2017 Jun; 46(12):3830-3852. PubMed ID: 28516983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stromal disruption facilitating invasion of a 'nano-arsenal' into the solid tumor.
    Fu Y; Saraswat AL; Monpara J; Patel K
    Drug Discov Today; 2022 Apr; 27(4):1132-1141. PubMed ID: 34823002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
    Kim J; Cho H; Lim DK; Joo MK; Kim K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.